Medical Management of Tumor Lysis Syndrome, Postprocedural Pain, and Venous Thromboembolism Following Interventional Radiology Procedures

Ali Faramarzalian; Keith B. Armitage; Baljendra Kapoor; Sanjeeva P. Kalva

doi:10.1055/s-0035-1549379

Seminars in Interventional Radiology, Table of Contents

Semin intervent Radiol 2015; 32(02): 209-216
DOI: 10.1055/s-0035-1549379

Review Article

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Medical Management of Tumor Lysis Syndrome, Postprocedural Pain, and Venous Thromboembolism Following Interventional Radiology Procedures

Authors

Ali Faramarzalian

¹Department of Internal Medicine, University Hospitals Case Medical Center, Cleveland, Ohio
Keith B. Armitage

¹Department of Internal Medicine, University Hospitals Case Medical Center, Cleveland, Ohio
Baljendra Kapoor

²Department of Radiology, Cleveland Clinic, Cleveland, Ohio
Sanjeeva P. Kalva

³Division of Interventional Radiology, Department of Radiology, University of Texas Southwestern Medical Center, Dallas, Texas

Abstract

The rapid expansion of minimally invasive image-guided procedures has led to their extensive use in the interdisciplinary management of patients with vascular, hepatobiliary, genitourinary, and oncologic diseases. Given the increased availability and breadth of these procedures, it is important for physicians to be aware of common complications and their management. In this article, the authors describe management of select common complications from interventional radiology procedures including tumor lysis syndrome, acute on chronic postprocedural pain, and venous thromboembolism. These complications are discussed in detail and their medical management is outlined according to generally accepted practice and evidence from the literature.

Keywords

interventional radiology complications - venous thromboembolism - tumor lysis syndrome - postprocedural pain - medical management

Full Text

References

References
1 Cardella JF, Kundu S, Miller DL, Millward SF, Sacks D ; Society of Interventional Radiology. Society of Interventional Radiology clinical practice guidelines. J Vasc Interv Radiol 2009; 20 (7, Suppl): S189-S191
2 Sewani HH, Rabatin JT. Acute tumor lysis syndrome in a patient with mixed small cell and non-small cell tumor. Mayo Clin Proc 2002; 77 (7) 722-728
3 Rostom AY, El-Hussainy G, Kandil A, Allam A. Tumor lysis syndrome following hemi-body irradiation for metastatic breast cancer. Ann Oncol 2000; 11 (10) 1349-1351
4 Mirrakhimov AE, Ali AM, Khan M, Barbaryan A. Tumor lysis syndrome in solid tumors: an up to date review of the literature. Rare Tumors 2014; 6 (2) 5389
5 Lehner SG, Gould JE, Saad WE, Brown DB. Tumor lysis syndrome after radiofrequency ablation of hepatocellular carcinoma. AJR Am J Roentgenol 2005; 185 (5) 1307-1309
6 Lee CC, Wu YH, Chung SH, Chen WJ. Acute tumor lysis syndrome after thalidomide therapy in advanced hepatocellular carcinoma. Oncologist 2006; 11 (1) 87-88 , author reply 89
7 Hsieh PM, Hung KC, Chen YS. Tumor lysis syndrome after transarterial chemoembolization of hepatocellular carcinoma: case reports and literature review. World J Gastroenterol 2009; 15 (37) 4726-4728
8 Sakamoto N, Monzawa S, Nagano H, Nishizaki H, Arai Y, Sugimura K. Acute tumor lysis syndrome caused by transcatheter oily chemoembolization in a patient with a large hepatocellular carcinoma. Cardiovasc Intervent Radiol 2007; 30 (3) 508-511
9 Burney IA. Acute tumor lysis syndrome after transcatheter chemoembolization of hepatocellular carcinoma. South Med J 1998; 91 (5) 467-470
10 Huang WS, Yang CH. Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient. World J Gastroenterol 2009; 15 (35) 4464-4466
11 Shiozawa K, Watanabe M, Takenaka H , et al. Tumor lysis syndrome after sorafenib for hepatocellular carcinoma: a case report. Hepatogastroenterology 2010; 57 (101) 688-690
12 Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 2004; 127 (1) 3-11
13 Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med 2011; 364 (19) 1844-1854
14 Wilson FP, Berns JS. Onco-nephrology: tumor lysis syndrome. Clin J Am Soc Nephrol 2012; 7 (10) 1730-1739
15 Goldman SC, Holcenberg JS, Finklestein JZ , et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 2001; 97 (10) 2998-3003
16 McBride A, Westervelt P. Recognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignancies. J Hematol Oncol 2012; 5: 75
17 Caraceni A, Portenoy RK ; International Association for the Study of Pain. An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. Pain 1999; 82 (3) 263-274
18 Titton RL, Lucey BC, Gervais DA, Boland GW, Mueller PR. Celiac plexus block: a palliative tool underused by radiologists. AJR Am J Roentgenol 2002; 179 (3) 633-636
19 England A, Tam CL, Thacker DE , et al. Patterns, incidence and predictive factors for pain after interventional radiology. Clin Radiol 2005; 60 (11) 1188-1194
20 Kehlet H, Jensen TS, Woolf CJ. Persistent postsurgical pain: risk factors and prevention. Lancet 2006; 367 (9522) 1618-1625
21 Worthington-Kirsch R, Spies JB, Myers ER , et al; FIBROID Investigators. The Fibroid Registry for outcomes data (FIBROID) for uterine embolization: short-term outcomes. Obstet Gynecol 2005; 106 (1) 52-59
22 Volkers NA, Hehenkamp WJ, Birnie E , et al. Uterine artery embolization in the treatment of symptomatic uterine fibroid tumors (EMMY trial): periprocedural results and complications. J Vasc Interv Radiol 2006; 17 (3) 471-480
23 Bruno J, Sterbis K, Flick P , et al. Recovery after uterine artery embolization for leiomyomas: a detailed analysis of its duration and severity. J Vasc Interv Radiol 2004; 15 (8) 801-807
24 Siskin GP, Stainken BF, Dowling K, Meo P, Ahn J, Dolen EG. Outpatient uterine artery embolization for symptomatic uterine fibroids: experience in 49 patients. J Vasc Interv Radiol 2000; 11 (3) 305-311
25 Chou R, Fanciullo GJ, Fine PG , et al; American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009; 10 (2) 113-130
26 Rasuli P, Jolly EE, Hammond I , et al. Superior hypogastric nerve block for pain control in outpatient uterine artery embolization. J Vasc Interv Radiol 2004; 15 (12) 1423-1429
27 Lammer J, Malagari K, Vogl T , et al; PRECISION V Investigators. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33 (1) 41-52
28 Pomoni M, Malagari K, Moschouris H , et al. Post embolization syndrome in doxorubicin eluting chemoembolization with DC bead. Hepatogastroenterology 2012; 59 (115) 820-825
29 Brown DB, Geschwind JF, Soulen MC, Millward SF, Sacks D. Society of Interventional Radiology position statement on chemoembolization of hepatic malignancies. J Vasc Interv Radiol 2009; 20 (7, Suppl): S317-S323
30 Bern MM, Lokich JJ, Wallach SR , et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med 1990; 112 (6) 423-428
31 De Cicco M, Matovic M, Balestreri L , et al. Central venous thrombosis: an early and frequent complication in cancer patients bearing long-term silastic catheter. A prospective study. Thromb Res 1997; 86 (2) 101-113
32 Balestreri L, De Cicco M, Matovic M, Coran F, Morassut S. Central venous catheter-related thrombosis in clinically asymptomatic oncologic patients: a phlebographic study. Eur J Radiol 1995; 20 (2) 108-111
33 Monreal M, Alastrue A, Rull M , et al. Upper extremity deep venous thrombosis in cancer patients with venous access devices—prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost 1996; 75 (2) 251-253
34 Newman KA, Reed WP, Schimpff SC, Bustamante CI, Wade JC. Hickman catheters in association with intensive cancer chemotherapy. Support Care Cancer 1993; 1 (2) 92-97
35 Drakos PE, Nagler A, Or R, Gillis S, Slavin S, Eldor A. Low molecular weight heparin for Hickman catheter—induced thrombosis in thrombocytopenic patients undergoing bone marrow transplantation. Cancer 1992; 70 (7) 1895-1898
36 Kearon C, Akl EA. Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism. Blood 2014; 123 (12) 1794-1801
37 Pollack CV, Schreiber D, Goldhaber SZ , et al. Clinical characteristics, management, and outcomes of patients diagnosed with acute pulmonary embolism in the emergency department: initial report of EMPEROR (Multicenter Emergency Medicine Pulmonary Embolism in the Real World Registry). J Am Coll Cardiol 2011; 57 (6) 700-706
38 Wells PS, Anderson DR, Rodger M , et al. Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost 2000; 83 (3) 416-420
39 Le Gal G, Righini M, Roy PM , et al. Prediction of pulmonary embolism in the emergency department: the revised Geneva score. Ann Intern Med 2006; 144 (3) 165-171
40 Stein PD, Fowler SE, Goodman LR , et al; PIOPED II Investigators. Multidetector computed tomography for acute pulmonary embolism. N Engl J Med 2006; 354 (22) 2317-2327
41 Cossette B, Pelletier ME, Carrier N , et al. Evaluation of bleeding risk in patients exposed to therapeutic unfractionated or low-molecular-weight heparin: a cohort study in the context of a quality improvement initiative. Ann Pharmacother 2010; 44 (6) 994-1002
42 Prandoni P, Siragusa S, Girolami B, Fabris F ; BELZONI Investigators Group. The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study. Blood 2005; 106 (9) 3049-3054
43 Nazir SA, Ganeshan A, Nazir S, Uberoi R. Endovascular treatment options in the management of lower limb deep venous thrombosis. Cardiovasc Intervent Radiol 2009; 32 (5) 861-876
44 Heit JA. Predicting the risk of venous thromboembolism recurrence. Am J Hematol 2012; 87 (Suppl. 01) S63-S67
45 PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation 2005; 112 (3) 416-422
46 Kearon C, Akl EA, Comerota AJ , et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl) e419S-e494S
47 Lee AY, Levine MN, Baker RI , et al; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349 (2) 146-153
48 Hull RD, Pineo GF, Brant RF , et al; LITE Trial Investigators. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 2006; 119 (12) 1062-1072
49 Meyer G, Marjanovic Z, Valcke J , et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002; 162 (15) 1729-1735
50 Deitcher SR, Kessler CM, Merli G, Rigas JR, Lyons RM, Fareed J ; ONCENOX Investigators. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost 2006; 12 (4) 389-396